晚期结直肠癌应用复方苦参注射液联合FOLFOX-4方案化疗的临床观察

目的：观察晚期结直肠癌应用复方苦参注射液联合FOLFOX-4方案治疗的安全性及疗效。方法：将62例患者随机分为2组,治疗组33例,采用复方苦参注射液联合FOLFOX-4方案化疗;对照组29例,单纯用FOLFOX-4方案化疗。比较两组近期实体瘤疗效、生活质量改善以及不良反应。结果：近期疗效有效率治疗组为36.5%,对照组为33.1%,两组比较无显著性差异（P〉0.05）。治疗组生活质量评分（KPS）好转率为57.6%,对照组为31.0%,两组比较有显著性差异（P〈0.05）。治疗组化疗后外周血WBC、Hb、PLT均降低,但对照组下降更为明显（P〈0.01）。结论：复方苦参注射液在晚期结直肠癌化疗中有增加疗效、减少不良反应、提高生存质量的作用。

Clinical Efficacy of Compound Matrine Injection in Combination with FOLFOX-4 Chemotherapy for Advanced Colorectal Cancer

OBJECTIVE： To evaluate the efficacy and safety of Compound Matrine injection in combination with FOLFOX-4 chemotherapy in the treatment of advanced colorectal cancer. METHODS： A total of 62 patients with advanced colorectal cancer were enrolled： 33 in the trial group were assigned to receive Compound Matrine injection in combination with FOLFOX-4 chemotherapy, and 29 in the control group to receive FOLFOX-4 chemotherapy alone. The short-term efficacy on solid tumor, improvement of life quality and side effects were compared between the two groups. RESULTS： There were no significant differences between the two groups in short-term response rate （36.5 % in the trial group vs. 33. 1% in the control group） （P 〉 0.05）. However, significant differences were noted between the two groups in the improvement rate of quality of life （56.5 % in the trial group vs. 31.8% in control group） （P 〈 0.05）. After chemotherapy, the trial group showed reduction in WBC, Hb and PLT, however, the reduction of WBC, Hb and PLT in the control group was more significant （ P 〈 0.01 ）. CONCLUSION ： Compound Matrine injection showed proved efficacy of attenuation and synergism while improving quality of life in the treatment of patients with advanced colorectal cancer.